A dangerous cross-contamination issue has forced a pharmaceutical company to recall an over-the-counter allergy medication. Several lots of widely used cetirizine hydrochloride tablets were potentially tainted with a completely different drug. This alarming manufacturing error could trigger life-threatening reactions in unsuspecting American consumers.
The U.S. Food and Drug Administration shared a notice confirming the voluntary nationwide recall. Unique Pharmaceutical Laboratories officially pulled four lots of the allergy tablets due to this cross-contamination risk. The medication is commonly used to treat everyday allergy symptoms like sneezing and irritated eyes.
Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine https://t.co/KQG3pxILWS pic.twitter.com/gjpFZuRjCL
— U.S. FDA Recalls (@FDArecalls) July 20, 2026
Investigators believe the allergy tablets were accidentally cross-contaminated with ranitidine during the manufacturing process. Ranitidine is an antihistamine that blocks stomach fluids and is primarily used by patients suffering from ulcers or severe heartburn. However, some consumers can be highly sensitive to the specific ingredients found in ranitidine.
The FDA recall notice explains that hypersensitive patients could experience serious adverse events if exposed. Some individuals could suffer from severe allergic reactions, including sudden drops in blood pressure and dangerous swelling in the throat. These terrifying symptoms are considered life-threatening and require immediate medical intervention.
A sharp-eyed pharmacy technician reportedly discovered the alarming contamination issue on the job. The worker noticed that some of the cetirizine hydrochloride tablets had a strange red dot and appeared discolored. Fortunately, the recall notice states there have been no reported adverse health incidents connected to the tainted medication so far.
The recalled medication was distributed nationwide in 100-tablet bottles by Rising Pharma Holdings Inc. The company has already started contacting impacted customers by email to arrange quick and efficient returns. Consumers with questions are encouraged to contact Rising Pharma Holdings during standard business hours at 1-844-874-7464.
This is not the first time ranitidine has been at the center of a major federal health concern. In 2020, the FDA successfully pressured manufacturers to pull ranitidine products off the market entirely. Some of these heartburn products contained low levels of a dangerous contaminant known to cause cancer.
Federal regulators finally allowed a newly reformulated version of ranitidine back onto the market last year. However, this recent cross-contamination recall raises fresh questions about overseas pharmaceutical manufacturing standards. Consumers rely on safe, uncontaminated products when they buy simple allergy relief over the counter.